DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has announced its participation in the upcoming Cantor Global Healthcare Conference scheduled for September 3-5, 2025, in New York City. Rick Pauls, President and CEO, along with Chief Business Officer Dave Wambeke, will engage in a fireside chat moderated by Joshua Schimmer, a Managing Director and Biotech Equity Research Analyst at Cantor Fitzgerald. This session is set for September 4, 2025, from 9:10 to 9:40 am ET, at the New York Marriott Marquis.

In addition to the fireside chat, management will be available for one-on-one meetings with investors, providing a platform for detailed discussions about their ongoing projects and future plans. DiaMedica Therapeutics aims to enhance the treatment of critical ischemic diseases, specializing in conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke.

The company's lead candidate, DM199, represents a significant advancement in the field as the first pharmaceutically active recombinant form of the KLK1 protein. KLK1 is already an established treatment in Asia for stroke, preeclampsia, and other vascular diseases, and its development in the U.S. market signifies DiaMedica's commitment to improving patient outcomes.

For additional information about DiaMedica and its innovative solutions, potential investors and interested parties can visit the company's website at www.diamedica.com. With a focus on addressing unmet medical needs in serious health conditions, DiaMedica Therapeutics continues to position itself as a forward-thinking entity within the biopharmaceutical landscape.

As DiaMedica Therapeutics Inc. (Nasdaq: DMAC) prepares to participate in the Cantor Global Healthcare Conference on September 4, 2025, investors should carefully consider both the potential and risks associated with this clinical-stage biopharmaceutical company. With a focus on developing treatments for significant conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke, DiaMedica aims to address unmet medical needs with its lead candidate, DM199, which is a recombinant form of the KLK1 protein. This compound has shown promise in Asia for treating acute ischemic stroke, providing a substantial groundwork for potential FDA approval.

The fireside chat led by Rick Pauls, CEO, and Dave Wambeke, CBO, is a crucial opportunity for investors to glean insights into the company's strategic direction and pipeline progress. With Josh Schimmer from Cantor Fitzgerald moderating, this discussion may present critical data on DM199's clinical efficacy, safety profile, and the timeline for upcoming clinical trials, which could significantly influence market sentiment.

Investors should remain cautious yet optimistic. While the therapeutic landscape for DM199 is compelling, the company's stage of development poses inherent risks, including regulatory hurdles and market competition. The success of upcoming clinical trials will be pivotal in determining the stock's trajectory. Given that the biotechnology sector is often characterized by volatility, holding a position in DiaMedica may necessitate a longer investment horizon, allowing time for potential clinical milestones to materialize.

In summary, monitoring DiaMedica's progress at the Cantor Global Healthcare Conference could be advantageous for investors seeking exposure to innovative treatment solutions in the biopharmaceutical domain. However, due diligence is essential, considering the inherent risks associated with investing in developmental-stage companies.